It appears Braveheart Bio isn’t going to let Big Pharma take its freedom anytime soon, as the company is aiming for a Nasdaq listing to move its phase 3 cardiovascular drug forward.
Source: FierceBiotech
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.